Section Arrow
Quote
CRNX.NASDAQ
- Crinetics Pharmaceuticals
Quotes are at least 15-min delayed:2026/03/09 15:40 EDT
Regular Hours
Last
 38.32
+0.06 (+0.16%)
Day High 
39.28 
Prev. Close
38.26 
1-M High
48.58 
Volume 
950.59K 
Bid
38.32
Ask
38.39
Day Low
37.75 
Open
38.25 
1-M Low
37.62 
Market Cap 
3.92B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 41.4 
20-SMA 43.09 
50-SMA 47.93 
52-W High 57.99 
52-W Low 24.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.95/-4.98
Enterprise Value
3.96B
Balance Sheet
Book Value Per Share
9.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.70M
Operating Revenue Per Share
0.05
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ANTXAN2 Therapeutics5.2401+2.4001+84.51%-- 
IBRXImmunityBio8.505-0.145-1.68%-- 
IOVAIovance Biotherapeutics5.425+0.29+5.65%-- 
RLMDRelmada Therapeutics7.28+2.83+63.60%-- 
QNCXQuince Therapeutics0.10765+0.00535+5.23%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.